Literature DB >> 21091667

Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis.

L M Stinton1, M Swain, R P Myers, A A Shaheen, M J Fritzler.   

Abstract

Autoantibodies to intracellular targets in mitochondria and nuclei are serological hallmarks of primary biliary cirrhosis (PBC). One of the most recently identified cellular targets of PBC autoantibodies is a novel cytoplasmic structure referred to as GW bodies [GWB, G (glycine) W (tryptophan)-containing bodies (GWB)]. GWB are indentified as discrete cytoplasmic domains that are involved in mRNA processing via the RNA interference (RNAi) pathway. Key components of GWB include the proteins GW182, Ago2, RNA-associated protein 55 (RAP55) and Ge-1/Hedls. The primary objective was to study the frequency and clinical association of antibodies directed to GWB components, in 109 PBC patients. Autoantibodies to mitochondrial antigen-pyruvate dehydrogenase complex (M2), branched-chain 2-oxo-acid dehydrogenase complex and 2-oxo glutarate dehydrogenase complex (3E-BPO), gp210, sp100, promyelocytic leukaemia cell antigen (PML) and liver kidney microsomal-1 antigen (LKM-1) were detected by a line immunoassay and antibodies to GWB (GW182, RAP55, Ge-1, GW2, GW3) and glutamate receptor interacting protein (GRIP)-associated protein-1 (GRASP-1), by an addressable laser bead immunoassay (ALBIA). The most common GWB autoantigen targets were: RAP55-28%, GW182-12%, GW2-2% and antibodies to GRASP-1-17%. By comparison, the frequency of reactivity to established PBC autoantigens was: gp210, 27%; sp100, 27% and PML, 17%. None of the autoantibodies were associated with differences in Mayo risk score or liver decompensation. This study is the first study to show that antibodies to RAP55, GW182 and GRASP-1 are the most common GWB targets in PBC.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21091667      PMCID: PMC3043305          DOI: 10.1111/j.1365-2249.2010.04288.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  69 in total

1.  Detection of anti-branched chain 2-oxo acid dehydrogenase complex (BCOADC)-E2 antibody in primary biliary cirrhosis by ELISA using recombinant fusion protein.

Authors:  H Miyakawa; K Abe; E Kitazawa; K Kikuchi; H Fujikawa; M Matsushita; N Kawaguchi; M Kako
Journal:  Autoimmunity       Date:  1999       Impact factor: 2.815

2.  Positive markers in AMA-negative PBC.

Authors:  Diego Vergani; Dimitrios Petrou Bogdanos
Journal:  Am J Gastroenterol       Date:  2003-02       Impact factor: 10.864

Review 3.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

4.  Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.

Authors:  E J Heathcote
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

Review 5.  Autoimmunity and primary biliary cirrhosis.

Authors:  I R Mackay
Journal:  Baillieres Best Pract Res Clin Gastroenterol       Date:  2000-08

6.  PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis.

Authors:  Alessandro Granito; Wei-Hong Yang; Luigi Muratori; Mark J Lim; Ayako Nakajima; Silvia Ferri; Georgios Pappas; Chiara Quarneti; Francesco B Bianchi; Donald B Bloch; Paolo Muratori
Journal:  Am J Gastroenterol       Date:  2009-10-27       Impact factor: 10.864

7.  RNA-associated protein 55 (RAP55) localizes to mRNA processing bodies and stress granules.

Authors:  Wei-Hong Yang; Jiang Hong Yu; Tod Gulick; Kenneth D Bloch; Donald B Bloch
Journal:  RNA       Date:  2006-02-16       Impact factor: 4.942

8.  Quantification of lupus anti-ribosome P antibodies using a recombinant P2 fusion protein and determination of the predicted amino acid sequence of the autoantigen in patients' mononuclear cells.

Authors:  J Magsaam; A E Gharavi; A P Parnassa; H Weissbach; N Brot; K B Elkon
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

9.  Detection of anti-double and anti-single stranded DNA antibodies in chronic liver disease: significance of anti-double stranded DNA antibody in autoimmune hepatitis.

Authors:  K Tsuchiya; K Kiyosawa; H Imai; T Sodeyama; S Furuta
Journal:  J Gastroenterol       Date:  1994-04       Impact factor: 7.527

10.  Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients.

Authors:  Shervin Assassi; Marvin J Fritzler; Frank C Arnett; Gary L Norman; Kairav R Shah; Pravitt Gourh; Neil Manek; Marilyn Perry; Devi Ganesh; Mohammad H Rahbar; Maureen D Mayes
Journal:  J Rheumatol       Date:  2009-09-01       Impact factor: 4.666

View more
  15 in total

1.  Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays.

Authors:  Chao-Jun Hu; Guang Song; Wei Huang; Guo-Zhen Liu; Chui-Wen Deng; Hai-Pan Zeng; Li Wang; Feng-Chun Zhang; Xuan Zhang; Jun Seop Jeong; Seth Blackshaw; Li-Zhi Jiang; Heng Zhu; Lin Wu; Yong-Zhe Li
Journal:  Mol Cell Proteomics       Date:  2012-05-30       Impact factor: 5.911

Review 2.  Precision autophagy directed by receptor regulators - emerging examples within the TRIM family.

Authors:  Tomonori Kimura; Michael Mandell; Vojo Deretic
Journal:  J Cell Sci       Date:  2016-02-15       Impact factor: 5.285

3.  Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease?

Authors:  Caroline Jefferies; Claire Wynne; Rowan Higgs
Journal:  Nat Rev Immunol       Date:  2011-08-25       Impact factor: 53.106

Review 4.  Bromodomains as therapeutic targets.

Authors:  Susanne Muller; Panagis Filippakopoulos; Stefan Knapp
Journal:  Expert Rev Mol Med       Date:  2011-09-13       Impact factor: 5.600

Review 5.  Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent.

Authors:  Marvin J Fritzler
Journal:  Auto Immun Highlights       Date:  2012-03-21

6.  Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis.

Authors:  Shi-Ling Hu; Feng-Rong Zhao; Qin Hu; Wei-Xian Chen
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

7.  Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.

Authors:  Laura M Stinton; Robert P Myers; Carla S Coffin; Marvin J Fritzler
Journal:  BMC Gastroenterol       Date:  2013-03-19       Impact factor: 3.067

8.  An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.

Authors:  Astrid Behnert; Marvin J Fritzler; Beina Teng; Meifeng Zhang; Frank Bollig; Hermann Haller; Andrej Skoberne; Michael Mahler; Mario Schiffer
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

9.  X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis.

Authors:  Rosanna Asselta; Elvezia M Paraboschi; Alessio Gerussi; Heather J Cordell; George F Mells; Richard N Sandford; David E Jones; Minoru Nakamura; Kazuko Ueno; Yuki Hitomi; Minae Kawashima; Nao Nishida; Katsushi Tokunaga; Masao Nagasaki; Atsushi Tanaka; Ruqi Tang; Zhiqiang Li; Yongyong Shi; Xiangdong Liu; Ma Xiong; Gideon Hirschfield; Katherine A Siminovitch; Marco Carbone; Giulia Cardamone; Stefano Duga; M Eric Gershwin; Michael F Seldin; Pietro Invernizzi
Journal:  Gastroenterology       Date:  2021-03-04       Impact factor: 33.883

Review 10.  Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015.

Authors:  Edward K L Chan; Jan Damoiseaux; Orlando Gabriel Carballo; Karsten Conrad; Wilson de Melo Cruvinel; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Ignacio Garcia-De La Torre; Manfred Herold; Tsuneyo Mimori; Minoru Satoh; Carlos A von Mühlen; Luis E C Andrade
Journal:  Front Immunol       Date:  2015-08-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.